Shattuck Labs, Inc. Stock Price, News & Analysis

Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.

Shattuck Labs (NASDAQ: STTK) announced the initiation of a Phase 1 clinical trial for its CD47 checkpoint inhibitor, SL-172154, targeting ovarian cancer. The company raised approximately $232.3 million in its October 2020 IPO, extending its cash runway into 2024. Financial results for Q3 2020 show a net loss of $11.8 million, increasing from $7.3 million in Q3 2019. R&D expenses rose to $11.8 million, up from $7.9 million in the same period last year. Shattuck remains focused on advancing its clinical trials and maintaining its pipeline through ongoing funding.

Shattuck Labs, a clinical-stage biotechnology firm (NASDAQ: STTK), announced the presentation of preclinical data from its GADLEN™ platform at the SITC Annual Meeting on November 11, 2020. The research showcases the potential of a butyrophilin heterodimer to activate gamma delta T cells, targeting lymphoma cells with the CD19 antigen. CEO Taylor Schreiber emphasized the promise of enhancing gamma delta T cell effectiveness for treating resistant cancers. This milestone represents significant progress in developing GADLEN compounds for various tumor targets.

Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.

Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its upcoming presentation at the virtual CD47|SIRPα Summit 2020 on November 5, 2020. The presentation, titled "CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity," will be delivered by CEO Taylor Schreiber at 10:45 a.m. EST. Shattuck is developing bi-functional fusion proteins targeting cancer and autoimmune diseases, with its lead program SL-172154 currently in a Phase 1 trial.

Shattuck Labs, a clinical-stage biotechnology company, will present at the TIGIT Therapies Digital Summit 2020 on October 26 at 10:00 a.m. EDT. The presentation, titled Using LIGHT to Hotwire TIGIT Blockade, will be led by CEO Taylor Schreiber. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune treatments through its unique ARC® platform. Their leading compound, SL-172154, is currently in a Phase 1 trial, alongside another compound, SL-279252, being tested with Takeda Pharmaceuticals. The presentation will be available for download on their website.

Shattuck Labs announced the successful closing of its upsized initial public offering, consisting of 13,664,704 shares at $17.00 each, garnering approximately $232.3 million in gross proceeds. The offering included the full exercise of underwriters' options for an additional 1,782,352 shares. All shares were offered by Shattuck, with trading on Nasdaq under the symbol STTK commencing on October 9, 2020. The company focuses on developing bi-functional fusion proteins for cancer and autoimmune disease treatments, with key programs currently in Phase 1 trials.

Shattuck Labs has announced the pricing of its upsized initial public offering, offering 11,882,352 shares of common stock at $17.00 each, aiming for gross proceeds of approximately $202 million. The shares will commence trading on Nasdaq under the symbol STTK on October 9, 2020. An additional 1,782,352 shares may be purchased by underwriters within 30 days of the offering. The offering is set to close on October 14, 2020, subject to customary conditions. Citigroup, Cowen, and Evercore ISI are joint book-running managers for this offering.